Category - Markets

Roth Capital Partners launched coverage of ArQule (NASDAQ:ARQL) with a “buy” rating and $5 price target. The stock closed at $1.67 on Feb. 21. “We believe that the value-driving components of the pipeline have been in...

Stifel upgraded Momenta Pharmaceuticals (NASDAQ:MNTA) to “buy” from “hold” and raised its price target to $21 from $18. The stock closed at $16.35 on Feb. 21. “As part of our stock call, we acknowledge two opposing...

Roth Capital Partners initiated coverage of Anthera Pharmaceuticals (NASDAQ:ANTH) with a “buy” rating and $10 price target. The stock closed at $1.69 on Feb. 20. The company’s value driver, Sollpura, is an oral...

Analysts for Ladenburg Thalmann and Roth Capital Partners initiated coverage of Eyenovia (NASDAQ:EYEN) with “buy” ratings and price targets of $35 and $20, respectively. The stock closed at $9 on Feb. 16. Eyenovia...

Leerink launched coverage of resTORbio (NASDAQ:TORC) with an “outperform” rating and $36 price target. The stock closed at $18.76 on Feb. 16. “Our rating and valuation are based on our sales forecast for lead asset...

Leerink initiated coverage of Solid Biosciences (NASDAQ:SLDB) with an “outperform” rating and $36 price target. The stock closed at $24.93 on Feb. 16. “We are encouraged by the preclinical data generated for...

William Blair launched coverage of Acer Therapeutics (NASDAQ:ACER) with an “outperform” rating and fair value estimate of $47. The stock closed at $17 on Feb. 15. Acer is developing two late-stage clinical...

Maxim Group slashed its price target for Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC) to €6 from €12, citing the company’s data through mid-2019. The stock closed at €2.75 on Feb. 14...

Maxim Group downgraded Galmed Pharmaceuticals (NASDAQ:GLMD) to “hold” from “buy” and removed its previous $14 price target after the company announced that top-line results from the ARRIVE trial...

Maxim Group slashed its price target to Anavex Life Sciences (NASDAQ:AVXL) to $5 from $14, saying the company’s definitive proof-of-concept studies will take time and money. The stock closed at $2.54 on Feb. 13...